<DOC>
	<DOCNO>NCT03040999</DOCNO>
	<brief_summary>The purpose study determine efficacy safety pembrolizumab give concomitantly chemoradiation ( CRT ) maintenance therapy versus placebo plus CRT participant locally advanced head neck squamous cell carcinoma ( LA HNSCC ) . The primary hypothesis pembrolizumab combination CRT superior placebo combination CRT respect event-free survival ( EFS ) per Response Evaluation Criteria Solid Tumors ( RECIST ) version 1.1 blind independent central review ( BICR ) .</brief_summary>
	<brief_title>Study Pembrolizumab ( MK-3475 ) Placebo With Chemoradiation Participants With Locally Advanced Head Neck Squamous Cell Carcinoma ( MK-3475-412/KEYNOTE-412 )</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Pembrolizumab</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>Has pathologically proven new diagnosis oropharyngeal p16 positive , oropharyngeal p16 negative , larynx/hypopharynx/oral cavity ( independent p16 ) squamous cell carcinoma . Participants oral cavity tumor need unresectable disease . Has provide adequate tissue Programmed Cell Death Receptor Ligand 1 ( PDL1 ) biomarker analysis core excisional biopsy Has evaluable tumor burden ( measurable and/or nonmeasurable tumor lesion ) assess compute tomography scan magnetic resonance imaging , base RECIST version 1.1 Is eligible definitive CRT consider primary surgery base investigator decision Has Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 perform within 10 day prior receive first dose study therapy Female participant childbearing potential must negative urine serum pregnancy test within 72 hour prior receive first dose study therapy Female male participant reproductive potential must agree use adequate contraception throughout study period 180 day last dose study therapy Is currently participate participate study investigational agent use investigational device within 4 week first dose study therapy Has receive prior therapy antiProgrammed Cell Death Receptor 1 ( PD1 ) , antiPDL1 , antiProgrammed Cell Death Receptor Ligand 2 ( PDL2 ) agent agent direct another coinhibitory Tcell receptor previously participate clinical study pembrolizumab Has receive live vaccine within 30 day prior first dose study therapy Has cancer outside oropharynx , larynx , hypopharynx oral cavity , nasopharyngeal , sinus , paranasal , unknown primary head neck cancer Has prior systemic therapy , target therapy , radiotherapy treatment radical surgery head neck cancer study Has recover major surgery prior start study therapy Has know active Hepatitis B C Has know history Human Immunodeficiency Virus ( HIV ) Has diagnosis immunodeficiency receive systemic steroid therapy form immunosuppressive therapy within 7 day prior first dose study therapy Has history ( noninfectious ) pneumonitis require steroid current pneumonitis Has active autoimmune disease require systemic treatment past 2 year . Replacement therapy consider form systemic treatment . Has history diagnose and/or treat hematologic primary solid tumor malignancy , unless remission least 5 year prior randomization Has know active central nervous system ( CNS ) metastases and/or carcinomatous meningitis Has previous allogeneic tissue/solid organ transplant Has active infection require systemic therapy Has history severe hypersensitivity reaction pembrolizumab , cisplatin radiotherapy analog Is pregnant breast feeding expect conceive father child throughout study period 180 day last dose study therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Head Neck Squamous Cell Carcinoma</keyword>
	<keyword>Programmed Cell Death Receptor 1 ( PD-1 )</keyword>
	<keyword>Programmed Cell Death Receptor Ligand 1 ( PD-L1 )</keyword>
	<keyword>Programmed Cell Death Receptor Ligand 2 ( PD-L2 )</keyword>
	<keyword>PD1</keyword>
	<keyword>PD-1</keyword>
	<keyword>PDL1</keyword>
	<keyword>PD-L1</keyword>
	<keyword>PDL2</keyword>
</DOC>